Liothyronine sodium - Hypothyroidism with intolerance to levothyroxine
You are here : Home > Formulary Search > Liothyronine sodium - Hypothyroidism with intolerance to levothyroxine
Status 1
- Capsules
- Tablets
Initiation by consultant endocrinologists and stabilisation for at least 3 months before requesting shared care.
Capsules are considerably lower cost than the tablets in Primary Care.
Patients receiving tablets in primary care may be switched to capsules (licensed and bioequivalent).
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
Status 2
- Oral solution
The oral solution has not been reviewed for addition to the formulary. Please contact your Pharmacy Team for advice.
This formulation has not yet been assessed for formulary status and is not currently on the APC work-plan.
It has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing, it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net if they wish to make a submission.
Documentation
PAD Profile
Other Indications
Below are listed other indications that Liothyronine sodium is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Hypothyroidism with intolerance to levothyroxine.
- No records returned.
Committee Recommendations (3)
This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.
Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).
See narrative below (June 2019) for recommend use.
NOTE:
Licensed, bioequivalent liothyronine CAPSULES have entered the market at a considerably reduced price and the APC recommend that:
- the most cost effective preparation should be prescribed (currently capsules) in all new patients
- prescribers should consider switching existing patients from tablets to capsules - for discussion with the patient at next review
The APC noted the additional information provided in the Liothyronine capsules - briefing paper below
The Surrey and North West Sussex APC recommends the use of liothyronine (T3) monotherapy initiated only by consultant endocrinologists in an NHS consultation for patients with an intolerance to levothyroxine (T4).
Transfer of prescribing to primary care is supported for those patients that have had a satisfactory response for at least 3 months prior to transfer to primary care.
Liothyronine for this indication will be considered as AMBER on the traffic light system. Shared-care documentation is available below.
Patients taking liothyronine (monotherapy or in combination) prior to NHS England guidance ‘Items that should not routinely be prescribed in primary care’ (Nov 2017) should have been reviewed by an NHS consultant endocrinologist.